Form 4: Werewolf Therapeutics Director Meeta Chatterjee Granted Stock Options

Werewolf Therapeutics, Inc. Director Meeta Chatterjee was granted 27,000 stock options with an exercise price of $1.29 per share, vesting over one year or until the next annual meeting.

Summary

• Meeta Chatterjee, a Director of Werewolf Therapeutics, Inc. (HOWL), was granted 27,000 stock options.
• The stock options have an exercise price of $1.29 per share.
• The grant date for these options was June 12, 2025.
• The options vest in full on the earlier of the first anniversary of the grant date (June 12, 2026) or the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Ms. Chatterjee's continued service as a director.
• The options have an expiration date of June 11, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal of alignment between management/board and shareholder interests, and is a standard component of executive compensation.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company, potentially incentivizing better governance and strategic decisions.
• This is a standard form of compensation for directors, indicating routine corporate operations.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not provide a future outlook for the company's operations or financial performance.

Industry Context

This filing is a routine insider transaction report specific to Werewolf Therapeutics, Inc. and does not provide information relevant to broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The grant of 27,000 stock options to Director Meeta Chatterjee constitutes a related party transaction, as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The granted stock options will vest in full on the earlier of June 12, 2026 (first anniversary of grant date) or the next annual meeting of stockholders, subject to the reporting person's continued service as a director.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership